Rottapharm bought by Meda, beating valuation in pulled IPO
Rottapharm Madaus, the Italian drug firm that pulled its IPO amid tough markets just three weeks ago, has been acquired by a Swedish peer company at a valuation nearly 20% above the top of the range in the failed IPO. Meda will finance the €2.3bn deal through the debt and equity markets.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts